TABLE 1.
Cumulative frequency distribution of omadacycline MIC results for S. aureus for Europe and North America
| Organism (no. of isolates)a | Yr | No. (cumulative %) of isolates inhibited by omadacycline MIC (μg/ml) of: |
MIC50 (μg/ml) | MIC90 (μg/ml) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ≤0.015 | 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | ||||
| S. aureus | ||||||||||||
| NA (250) | 2014 | 2 (0.8) | 125 (50.8) | 102 (91.6) | 3 (92.8) | 7 (95.6) | 11 (100.0) | 0.06 | 0.12 | |||
| NA (4,881) | 2010 | 20 (0.4) | 346 (7.5) | 2,919 (67.3) | 1247 (92.8) | 215 (97.3) | 101 (99.3) | 29. (99.9) | 4 (100.0) | 0.12 | 0.25 | |
| EU (252) | 2014 | 9 (3.6) | 82 (36.1) | 151 (96.0) | 6 (98.4) | 3 (99.6) | 1 (100.0) | 0.12 | 0.12 | |||
| EU (2,859) | 2010 | 2 (0.1) | 21 (0.8) | 243 (9.3) | 1,752 (70.6) | 696 (94.9) | 134 (99.6) | 8 (99.9) | 3 (100.0) | 0.12 | 0.25 | |
| MSSA | ||||||||||||
| NA (50) | 2014 | 17 (34.0) | 32 (98.0) | 1 (100.0) | 0.12 | 0.12 | ||||||
| NA (2,373) | 2010 | 14 (0.6) | 178 (8.1) | 1,457 (69.5) | 628 (96.0) | 82 (99.4) | 11 (99.9) | 3 (100.0) | 0.12 | 0.25 | ||
| EU (50) | 2014 | 1 (2.0) | 13 (28.0) | 35 (98.0) | 0 (98.0) | 1 (100.0) | 0.12 | 0.12 | ||||
| EU (2,109) | 2010 | 2 (0.1) | 15 (0.8) | 204 (10.5) | 1,333 (73.7) | 461 (95.5) | 90 (99.8) | 3 (>99.9) | 1 (100.0) | 0.12 | 0.25 | |
| MRSA | ||||||||||||
| NA (200) | 2014 | 2 (1.0) | 108 (55.0) | 70 (90.0) | 2 (91.0) | 7 (94.5) | 11 (100.0) | 0.06 | 0.12 | |||
| NA (2,508) | 2010 | 6 (0.2) | 168 (6.9) | 1,462 (65.2) | 619 (89.9) | 133 (95.2) | 90 (98.8) | 26 (99.8) | 4 (100.0) | 0.12 | 0.5 | |
| EU (202) | 2014 | 8 (4.0) | 69 (68.1) | 116 (95.5) | 6 (98.5) | 2 (99.5) | 1 (100.0) | 0.12 | 0.12 | |||
| EU (750) | 2010 | 6 (0.8) | 39 (6.0) | 419 (61.9) | 235 (93.2) | 44 (99.1) | 5 (99.7) | 2 (100.0) | 0.12 | 0.25 | ||
| Hospital-acquired MRSA | ||||||||||||
| NA (101) | 2014 | 45 (44.6) | 44 (88.1) | 0 (88.1) | 6 (94.1) | 6 (100.0) | 0.12 | 0.5 | ||||
| NA (497) | 2010 | 28 (5.6) | 280 (62.0) | 114 (84.9) | 29 (90.7) | 36 (98.0) | 9 (99.8) | 1 (100.0) | 0.12 | 0.5 | ||
| EU (102) | 2014 | 5 (4.9) | 35 (39.2) | 55 (93.1) | 4 (97.1) | 2 (99.0) | 1 (100.0) | 0.12 | 0.12 | |||
| EU (379) | 2010 | 2 (0.5) | 13 (4.0) | 208 (58.8) | 124 (91.6) | 27 (98.7) | 4 (99.7) | 1 (100.0) | 0.12 | 0.25 | ||
| Community-acquired MRSA | ||||||||||||
| NA (99) | 2014 | 2 (2.0) | 63 (65.7) | 26 (91.9) | 2 (93.9) | 1 (94.9) | 5 (100.0) | 0.12 | 0.25 | |||
| NA (1,461) | 2010 | 4 (0.3) | 110 (7.8) | 869 (67.3) | 362 (92.1) | 78 (97.4) | 27 (99.2) | 10 (99.9) | 1 (100.0) | 0.12 | 0.25 | |
| EU (100) | 2014 | 3 (3.0) | 34 (37.0) | 61 (98.0) | 2 (100.0) | 0.12 | 0.12 | |||||
| EU (233) | 2010 | 3 (1.3) | 22 (10.7) | 125 (64.4) | 70 (94.4) | 12 (99.6) | 1 (100.0) | 0.12 | 0.25 | |||
a
Abbreviations: NA, North America; EU, Europe.